全文获取类型
| 收费全文 | 255938篇 |
| 免费 | 18116篇 |
| 国内免费 | 1132篇 |
专业分类
| 耳鼻咽喉 | 2828篇 |
| 儿科学 | 6636篇 |
| 妇产科学 | 4709篇 |
| 基础医学 | 33386篇 |
| 口腔科学 | 4627篇 |
| 临床医学 | 25882篇 |
| 内科学 | 54334篇 |
| 皮肤病学 | 3408篇 |
| 神经病学 | 24521篇 |
| 特种医学 | 8569篇 |
| 外国民族医学 | 11篇 |
| 外科学 | 38898篇 |
| 综合类 | 3513篇 |
| 一般理论 | 320篇 |
| 预防医学 | 21833篇 |
| 眼科学 | 6721篇 |
| 药学 | 17278篇 |
| 6篇 | |
| 中国医学 | 364篇 |
| 肿瘤学 | 17342篇 |
出版年
| 2023年 | 1349篇 |
| 2022年 | 2435篇 |
| 2021年 | 5495篇 |
| 2020年 | 3302篇 |
| 2019年 | 5344篇 |
| 2018年 | 6005篇 |
| 2017年 | 4517篇 |
| 2016年 | 5001篇 |
| 2015年 | 5879篇 |
| 2014年 | 8681篇 |
| 2013年 | 11885篇 |
| 2012年 | 18157篇 |
| 2011年 | 19067篇 |
| 2010年 | 10673篇 |
| 2009年 | 9508篇 |
| 2008年 | 16724篇 |
| 2007年 | 17600篇 |
| 2006年 | 17461篇 |
| 2005年 | 17429篇 |
| 2004年 | 16324篇 |
| 2003年 | 15199篇 |
| 2002年 | 14207篇 |
| 2001年 | 2238篇 |
| 2000年 | 1729篇 |
| 1999年 | 2424篇 |
| 1998年 | 3102篇 |
| 1997年 | 2585篇 |
| 1996年 | 2216篇 |
| 1995年 | 2129篇 |
| 1994年 | 1782篇 |
| 1993年 | 1603篇 |
| 1992年 | 1346篇 |
| 1991年 | 1276篇 |
| 1990年 | 1104篇 |
| 1989年 | 1090篇 |
| 1988年 | 1044篇 |
| 1987年 | 1040篇 |
| 1986年 | 1032篇 |
| 1985年 | 1050篇 |
| 1984年 | 1266篇 |
| 1983年 | 1170篇 |
| 1982年 | 1410篇 |
| 1981年 | 1339篇 |
| 1980年 | 1173篇 |
| 1979年 | 765篇 |
| 1978年 | 795篇 |
| 1977年 | 669篇 |
| 1976年 | 613篇 |
| 1975年 | 504篇 |
| 1974年 | 513篇 |
排序方式： 共有10000条查询结果，搜索用时 0 毫秒
41.
42.
43.
44.
45.
46.
Maggie L. Westfal David C. Chang Cassandra M. Kelleher 《Journal of pediatric surgery》2019,54(1):140-144
Purpose
The purpose of this study was to evaluate trends in demographics and outcomes of pediatric breast cancer in a United States population-based cohort.Methods
The Surveillance, Epidemiology, and End Results (SEER) database was utilized to identify all pediatric patients with malignant breast tumors between 1973 and 2014. Analysis was performed using Stata Statistical Software version 13.1. Associations between categorical variables were made using X2 test. Log-rank test was used for univariate survival analysis. Kaplan–Meier analysis investigated five-year survival rates across several variables. Adjusted analysis was performed using a Cox Proportional-Hazards regression.Results
134 patients with breast malignancies were identified. Carcinoma was the most prevalent histology (48.5%), followed by fibroepithelial tumors (FETs) (35.1%), and sarcoma (14.2%). FETs were twice as common in black compared to nonblack patients (56.3% vs. 29.0%, p?<?0.01). Analyzing histology by stage revealed that 100% of FETs were early stage disease (p?<?0.0001). 46.7% of the tumors tested were ER/PR negative, more than twice as many compared to the published adult estimate of 20.0%. Unadjusted survival analysis revealed worse survival for patients with adenocarcinoma/sarcomas, advanced stage, and high grade disease, without a survival difference between races.Conclusion
Breast cancer remains a rare malignancy among pediatric patients. Although black patients were found to have more noncarcinomatous tumors with less advanced disease, this did not confer a survival advantage.Type of study
Retrospective cohort study.Level of evidence
Level III. 相似文献47.
Julie A. Schmidt Georgina K. Fensom Sabina Rinaldi Augustin Scalbert Paul N. Appleby David Achaintre Audrey Gicquiau Marc J. Gunter Pietro Ferrari Rudolf Kaaks Tilman Kühn Heiner Boeing Antonia Trichopoulou Anna Karakatsani Eleni Peppa Domenico Palli Sabina Sieri Rosario Tumino Bas Bueno-de-Mesquita Antonio Agudo Maria-Jose Sánchez María-Dolores Chirlaque Eva Ardanaz Nerea Larrañaga Aurora Perez-Cornago Nada Assi Elio Riboli Konstantinos K. Tsilidis Timothy J. Key Ruth C. Travis 《International journal of cancer. Journal international du cancer》2020,146(3):720-730
Metabolomics may reveal novel insights into the etiology of prostate cancer, for which few risk factors are established. We investigated the association between patterns in baseline plasma metabolite profile and subsequent prostate cancer risk, using data from 3,057 matched case–control sets from the European Prospective Investigation into Cancer and Nutrition (EPIC). We measured 119 metabolite concentrations in plasma samples, collected on average 9.4 years before diagnosis, by mass spectrometry (AbsoluteIDQ p180 Kit, Biocrates Life Sciences AG). Metabolite patterns were identified using treelet transform, a statistical method for identification of groups of correlated metabolites. Associations of metabolite patterns with prostate cancer risk (OR1SD) were estimated by conditional logistic regression. Supplementary analyses were conducted for metabolite patterns derived using principal component analysis and for individual metabolites. Men with metabolite profiles characterized by higher concentrations of either phosphatidylcholines or hydroxysphingomyelins (OR1SD = 0.77, 95% confidence interval 0.66–0.89), acylcarnitines C18:1 and C18:2, glutamate, ornithine and taurine (OR1SD = 0.72, 0.57–0.90), or lysophosphatidylcholines (OR1SD = 0.81, 0.69–0.95) had lower risk of advanced stage prostate cancer at diagnosis, with no evidence of heterogeneity by follow-up time. Similar associations were observed for the two former patterns with aggressive disease risk (the more aggressive subset of advanced stage), while the latter pattern was inversely related to risk of prostate cancer death (OR1SD = 0.77, 0.61–0.96). No associations were observed for prostate cancer overall or less aggressive tumor subtypes. In conclusion, metabolite patterns may be related to lower risk of more aggressive prostate tumors and prostate cancer death, and might be relevant to etiology of advanced stage prostate cancer. 相似文献
48.
Béla Nagy Zsolt Bene Zsolt Fejes Sonya L. Heltshe David Reid Nicola J. Ronan Yvonne McCarthy Daniel Smith Attila Nagy Elizabeth Joseloff György Balla János Kappelmayer Milan Macek Scott C. Bell Barry J. Plant Margarida D. Amaral István Balogh 《Journal of cystic fibrosis》2019,18(2):271-277
Background
We have recently shown that human epididymis protein 4 (HE4) levels correlate with the severity of cystic fibrosis (CF) lung disease. However, there are no data on how HE4 levels alter in patients receiving CFTR modulating therapy.Methods
In this retrospective clinical study, 3 independent CF patient cohorts (US-American: 29, Australian: 12 and Irish: 19 cases) were enrolled carrying at least one Class III CFTR CF-causing mutation (p.Gly551Asp) and being treated with CFTR potentiator ivacaftor. Plasma HE4 was measured by immunoassay before treatment (baseline) and 1–6?months after commencement of ivacaftor, and were correlated with FEV1 (% predicted), sweat chloride, C-reactive protein (CRP) and body mass index (BMI).Results
After 1?month of therapy, HE4 levels were significantly lower than at baseline and remained decreased up to 6?months. A significant inverse correlation between absolute and delta values of HE4 and FEV1 (r?=??0.5376; P?<?.001 and r?=??0.3285; P?<?.001), was retrospectively observed in pooled groups, including an independent association of HE4 with FEV1 by multiple regression analysis (β?=??0.57, P?=?.019). Substantial area under the receiver operating characteristic curve (ROC-AUC) value was determined for HE4 when 7% mean change of FEV1 (0.722 [95% CI 0.581–0.863]; P?=?.029) were used as classifier, especially in the first 2?months of treatment (0.806 [95% CI 0.665–0.947]; P?<?.001).Conclusions
This study shows that plasma HE4 levels inversely correlate with lung function improvement in CF patients receiving ivacaftor. Overall, this potential biomarker may be of value for routine clinical and laboratory follow-up of CFTR modulating therapy. 相似文献49.
50.